These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 6152493)
1. The validation of animal tests of anxiety--pharmacological implications. File SE Pol J Pharmacol Pharm; 1984; 36(5):505-12. PubMed ID: 6152493 [TBL] [Abstract][Full Text] [Related]
3. Animal models of anxiety and benzodiazepine actions. Iversen SD Arzneimittelforschung; 1980; 30(5a):862-8. PubMed ID: 6106486 [TBL] [Abstract][Full Text] [Related]
4. [The neurochemical profile of the septal nucleus accumbens in the anxiolytic action of tranquilizers on different models of anxiety]. Talalaenko AN; Panfilov VIu; Vozdigan SA; Pokramovich AI; Markova OP; Okhrimenko SV Eksp Klin Farmakol; 1997; 60(4):7-9. PubMed ID: 9376765 [TBL] [Abstract][Full Text] [Related]
5. Protein synthesis and the mechanisms of lasting change in anxiety induced by severe stress. Adamec R; Strasser K; Blundell J; Burton P; McKay DW Behav Brain Res; 2006 Feb; 167(2):270-86. PubMed ID: 16256211 [TBL] [Abstract][Full Text] [Related]
6. The CRF(1) receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats. McElroy JF; Ward KA; Zeller KL; Jones KW; Gilligan PJ; He L; Lelas S Psychopharmacology (Berl); 2002 Dec; 165(1):86-92. PubMed ID: 12474122 [TBL] [Abstract][Full Text] [Related]
7. The pituitary mediates the anxiolytic-like effects of the vasopressin V1B receptor antagonist, SSR149415, in a social interaction test in rats. Shimazaki T; Iijima M; Chaki S Eur J Pharmacol; 2006 Aug; 543(1-3):63-7. PubMed ID: 16843459 [TBL] [Abstract][Full Text] [Related]
8. [The anxiolytic activity of calcium-channel blockers in tests of anxious behavior in mice and rats]. Kozlovskiĭ VL Zh Vyssh Nerv Deiat Im I P Pavlova; 1999; 49(1):84-95. PubMed ID: 10330709 [TBL] [Abstract][Full Text] [Related]
9. Animal models for predicting clinical efficacy of anxiolytic drugs: social behaviour. File SE Neuropsychobiology; 1985; 13(1-2):55-62. PubMed ID: 2863779 [TBL] [Abstract][Full Text] [Related]
10. [Peptides and anxiety]. Dantzer R Encephale; 1983; 9(4 Suppl 2):177B-182B. PubMed ID: 6144513 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the anxiolytic effects of chrysin, a Passiflora incarnata extract, in the laboratory rat. Brown E'; Hurd NS; McCall S; Ceremuga TE AANA J; 2007 Oct; 75(5):333-7. PubMed ID: 17966676 [TBL] [Abstract][Full Text] [Related]
17. Different pathways mediated by CCK1 and CCK2 receptors: effect of intraperitonal mrna antisense oligodeoxynucleotides to cholecystokinin on anxiety-like and learning behaviors in rats. Cohen H; Kaplan Z; Matar MA; Buriakovsky I; Bourin M; Kotler M Depress Anxiety; 2004; 20(3):139-52. PubMed ID: 15487014 [TBL] [Abstract][Full Text] [Related]
18. [The influence of calcium channel blockers on the effects of anxiogenic preparations]. Kozlovskiĭ VL Patol Fiziol Eksp Ter; 2000; (3):3-4. PubMed ID: 10983469 [TBL] [Abstract][Full Text] [Related]
19. Effects of central administration of gonadotropin-releasing hormone agonists and antagonist on elevated plus-maze and social interaction behavior in rats. Umathe SN; Bhutada PS; Jain NS; Dixit PV; Wanjari MM Behav Pharmacol; 2008 Jul; 19(4):308-16. PubMed ID: 18622178 [TBL] [Abstract][Full Text] [Related]
20. The alarm pheromone in male rats as a unique anxiety model: psychopharmacological evidence using anxiolytics. Inagaki H; Kiyokawa Y; Takeuchi Y; Mori Y Pharmacol Biochem Behav; 2010 Feb; 94(4):575-9. PubMed ID: 19969015 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]